Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer

Laia Monserrat, Judith García-García, Cristina Molina, Andreu Òdena, Taras Yuziv Duda, Irene Agustí-Barea, Gilles Flamen, Cristina Viaplana, Aerica Nagornyuk, Ruth Maldonado-Padrol, Claudia Yáñez-Bartolomé, Flaminia Pedretti, Marta Guzmán, Olga Rodríguez, Fara Brasó-Maristany, Eduardo García-Galea, Rodrigo Dienstmann, Motoki Takaku, Aleix Prat, Sarat Chandarlapaty, Julia Ponomarenko, Cristina Saura, Mafalda Oliveira, Lara Nonell, Meritxell Bellet, Guillermo P Vicent, Violeta Serra · 2026

Read Exploiting androgen receptor agonism as a treatment strategy in estrogen receptor-positive metastatic breast cancer by Laia Monserrat, Judith García-García, Cristina Molina, Andreu Òdena, Taras Yuziv Duda, Irene Agustí-Barea, Gilles Flamen, Cristina Viaplana, Aerica Nagornyuk, Ruth Maldonado-Padrol, Claudia Yáñez-Bartolomé, Flaminia Pedretti, Marta Guzmán, Olga Rodríguez, Fara Brasó-Maristany, Eduardo García-Galea, Rodrigo Dienstmann, Motoki Takaku, Aleix Prat, Sarat Chandarlapaty, Julia Ponomarenko, Cristina Saura, Mafalda Oliveira, Lara Nonell, Meritxell Bellet, Guillermo P Vicent, Violeta Serra (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13645744.txt.

Description

Laia Monserrat and twenty-six colleagues test a new treatment idea for metastatic breast cancer that responds to estrogen, in a 2026 study. Most such cancers also carry the androgen receptor, a target usually linked with male hormones. The team gave a drug called EP0062, which activates that receptor, to tumor models grown from patient tissue in mice. They compared its effect with drugs that block estrogen signaling.

The new drug shrank tumors about as well as the estrogen-blocking drugs, even in tumors carrying mutations linked with drug resistance. Tumors with changes in a gene called GATA3 seemed especially sensitive. Gene activity patterns tied to sensitivity were found, and adding a second drug helped some resistant tumors respond. The authors propose receptor activation as a fresh option for patients whose cancers no longer answer standard hormone therapy.

Catalog record

CREATORLaia Monserrat, Judith García-García, Cristina Molina, Andreu Òdena, Taras Yuziv Duda, Irene Agustí-Barea, Gilles Flamen, Cristina Viaplana, Aerica Nagornyuk, Ruth Maldonado-Padrol, Claudia Yáñez-Bartolomé, Flaminia Pedretti, Marta Guzmán, Olga Rodríguez, Fara Brasó-Maristany, Eduardo García-Galea, Rodrigo Dienstmann, Motoki Takaku, Aleix Prat, Sarat Chandarlapaty, Julia Ponomarenko, Cristina Saura, Mafalda Oliveira, Lara Nonell, Meritxell Bellet, Guillermo P Vicent, Violeta Serra
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE73228
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13645744

Browse the full library · About the Tower of Babel